Dr. Alshaygy on Resection Margin for Dermatofibrosarcoma Protuberans

Video

In Partnership With:

Ibrahim S. Alshaygy, MD, MSC, discusses research suggesting a smaller surgical resection margin for dermatofibrosarcoma protuberans.

Ibrahim S. Alshaygy, MD, MSC, a clinical fellow in Orthopedic Oncology at Mount Sinai Hospital, discusses research suggesting a smaller surgical resection margin for dermatofibrosarcoma protuberans (DFSP).

DFSP is an uncommon continuous tumor with a high local recurrence rate, explains Alshaygy. The current standard of care is to remove the tumor with a wide margin resection, but recent research shows that a negative margin can be achieved with smaller resections. Alshaygy and his research team also developed a new follow-up protocol depending on the pathological classification and grading for the tumor.

This research is expected to have a significant impact on the standard practice for this tumor type, according to Alshaygy. Currently, surgeons tend to go for a bigger and wider margin, but Alshaygy suggests a smaller incision. As long as a negative margin is achieved, enough tissue has been removed, which can lead to fewer adverse events, better cosmesis, and better functional outcomes for the patient, says Alshaygy. Additionally, the new follow-up protocol can impact the clinic follow-up and patient follow-up regimen, which saves physicians and patients time in the clinic, concludes Alshaygy.

Related Videos
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center